minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).
minjuvi pd.c.so.in 200 mg/vial
incyte biosciences distribution b.v., the netherlands paasheuvelweg 25, 1105 bp amsterdam - tafasitamab - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 200 mg/vial - tafasitamab 200mg - tafasitamab
talvey
janssen-cilag international n.v. - talquetamab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
talvey inj.sol 40 mg/1 ml
talquetamab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 40 mg/1 ml - talquetamab 40mg - talquetamab
talvey inj.sol 2mg/ml
talquetamab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 2mg/ml - talquetamab 2mg - talquetamab